Chronic kidney disease (CKD) is a serious condition affecting millions worldwide, and it can significantly impact a person's quality of life. For some individuals, the challenges of managing CKD can become a demanding, ongoing struggle, sometimes requiring frequent medical interventions.

CKD involves a gradual loss of kidney function. The kidneys' primary role is to filter waste and excess fluids from the blood, which are then excreted in urine. When kidneys lose their filtering ability, dangerous levels of fluid, electrolytes, and waste can build up in the body.

To manage CKD and prevent it from worsening, various treatments are available. These include medications like FARXIGA, which is approved to reduce the risk of further kidney disease progression, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD. Other drugs, such as rituximab, can help prevent the immune system from causing further damage to the kidneys. In addition to medication, lifestyle changes such as following a low-sodium diet, maintaining a healthy weight, and avoiding smoking are crucial in protecting the kidneys. Regular monitoring of kidney numbers, blood pressure, and blood sugar is also essential.

In some cases, CKD can progress to kidney failure, requiring dialysis or a kidney transplant. Dialysis is a procedure that filters the blood when the kidneys can no longer perform this function adequately. While dialysis can help prolong life, it can be a demanding and time-consuming process, often requiring frequent treatments.

Recent research has also explored the potential link between certain treatments and kidney disease. For example, a study in Taiwan found that intravitreal ranibizumab injection, a treatment for certain eye conditions, was associated with an increased risk of chronic kidney disease. This finding suggests that physicians and ophthalmologists should make patients aware of this potential correlation to increase patient safety and decrease the CKD burden.

Moreover, people with CKD are at a higher risk of bone fractures. Medications like denosumab can improve bone mineral density and reduce bone turnover in CKD patients. However, it's important to carefully assess patients and optimize CKD-mineral and bone disorders before starting denosumab, as it can lead to hypocalcemia (low calcium levels).

Managing CKD requires a multifaceted approach that includes medication, lifestyle changes, and regular monitoring. While treatments can help slow the progression of the disease and manage its symptoms, some interventions may also carry potential risks. Therefore, it's crucial for individuals with CKD to work closely with their healthcare team to make informed decisions about their treatment plan and to address any concerns or questions they may have.